TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The
hypothesis of this study is that TG100-115 can be given safely to patients who suffer a
heart attack and undergo angioplasty to restore blood flow. We will also evaluate whether
TG100-115 reduces heart muscle damage.
- Age 18-80 yrs
- ECG patterns consistent with an acute anterior myocardial infarction with ST segment
elevation of 2mm in two contiguous ECG leads among leads V1-V4.
- Have prolonged, continuous (lasting at least 20 mins) signs and symptoms of
myocardial ischemia not eliminated with nitrates.
- Intent to proceed to primary PCI within 6 hours of chest pain onset
- Sign an informed consent form and be willing to attend follow-up visits for safety
and other study assessments.
- Female of childbearing potential.
- History of previous myocardial infarction.
- History of congestive heart failure.
- Requirement for a cardiac pacemaker or defibrillator.
- Cardiogenic shock.
- Patients previously treated with thrombolytic therapy.
- Myocardial ischemia precipitated by a condition other than atherosclerotic coronary